DFTX surged 49.80% to close at $36.67 today after reporting positive topline results from its Phase 3 Emerge study of DT120 ODT in Major Depressive Disorder. - The stock is now trading at $35.00 (down 4.6% from its closing price) in after-hours trading. - This decline follows the announcement of a $500 million public offering of common shares and pre-funded warrants, which includes a 30-day option for underwriters to purchase up to an additional $75 million in shares. - The offering, announced after a significant rally, is contributing to profit-taking and potential share dilution concerns.